Results For the Financial Year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical reported FY25 revenue from operations of Rs 10,929.86 lakhs, nearly 2.8x the Rs 3,964.21 lakhs reported in FY24 — a sharp jump of about 176%. The Q4 standalone revenue alone was Rs 4,946.66 lakhs against Rs 1,055.24 lakhs in Q4 FY24. Despite the strong top-line growth, the company slipped deeper into losses with a net loss of Rs 1,029.83 lakhs for FY25 versus Rs 347.93 lakhs in FY24, and a loss before tax of Rs 1,435.14 lakhs. The company also reported an exceptional item of Rs 27 lakhs toward provident fund damages. The balance sheet shows negative other equity of Rs (6,262.40) lakhs, pushing total equity into negative territory at Rs (2,564.05) lakhs, while total borrowings rose sharply to over Rs 6,200 lakhs. Operating cash flow, however, turned positive at Rs 260.28 lakhs versus an outflow of Rs 1,304.96 lakhs in the previous year. The auditor (A.M Reddy & D.R Reddy) issued an unmodified opinion.
Strong revenue growth is a clear positive signal, but widening losses, negative net worth and rising borrowings raise serious concerns about the company's financial health and long-term sustainability. Shareholders should watch closely for any signs of equity infusion, debt reduction or a clear path to profitability, as the stock may remain volatile on these mixed signals.